A Study of Ibrutinib in Combination With Bendamustine and Rituximab in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Last updated: February 20, 2020
Sponsor: Janssen Research & Development, LLC
Overall Status: Completed

Phase

3

Condition

Lymphoma

Leukemia

Chronic Lymphocytic Leukemia

Treatment

N/A

Clinical Study ID

NCT01611090
CR100840
PCI-32765CLL3001
2012-000600-15
U1111-1135-3745
  • Ages > 18
  • All Genders

Study Summary

The purpose of this study is to examine the safety and efficacy of Ibrutinib administered in combination with bendamustine and rituximab in patients with relapsed or refractory chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL).

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Diagnosis of chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL)that meets protocol-defined criteria

  • Active disease meeting at least 1 of the International Workshop on Chronic LymphocyticLeukemia 2008 criteria for requiring treatment

  • Measurable nodal disease by computed tomography

  • Relapsed or refractory CLL or SLL following at least 1 prior line of systemic therapyconsisting of at least 2 cycles of a chemotherapy-containing regimen

  • Eastern Cooperative Oncology Group Performance Status score of 0 or 1

  • Hematology and biochemical values within protocol-defined limits

  • Agrees to protocol-defined use of effective contraception

  • Women of childbearing potential must have negative blood or urine pregnancy test atscreening

Exclusion

Exclusion Criteria:

  • Recent therapeutic interventions within 3 (chemotherapy/radiotherapy) to 10 weeks (immunotherapy)

  • Prior treatment with ibrutinib or other Bruton's tyrosine kinase inhibitors or priorrandomization in any other clinical study evaluating ibrutinib

  • The presence of deletion of the short arm of chromosome 17

  • Patients previously treated with a bendamustine-containing regimen who did not achievea response or who relapsed and required treatment within 24 months of treatment withthat regimen

  • Patients for whom the goal of therapy is tumor debulking prior to stem cell transplant

  • Received a hematopoietic stem cell transplant

  • Known central nervous system leukemia/lymphoma or Richter's transformation

  • Patients with uncontrolled autoimmune hemolytic anemia or autoimmune thrombocytopenia

  • Chronic use of corticosteroids

  • History of prior malignancy, except: malignancy treated with curative intent and withno known active disease present for >=3 years before randomization; adequately treatednon-melanoma skin cancer or lentigo maligna without evidence of disease; adequatelytreated cervical carcinoma in situ without evidence of disease

  • History of stroke or intracranial hemorrhage within 6 months prior to randomization;or clinically significant cardiovascular disease

  • Requires anticoagulation with warfarin or equivalent vitamin K antagonists ortreatment with strong CYP3A4/5 inhibitors

  • Known history of human immunodeficiency virus or hepatitis C, or active infection withhepatitis B or C

  • Any uncontrolled active systemic infection or any life-threatening illness, medicalcondition, or organ system dysfunction which, in the investigator's opinion, couldcompromise the patient's safety, interfere with the absorption or metabolism ofibrutinib capsules, or put the study outcomes at undue risk

  • A woman who is pregnant or breast feeding, or a man who plans to father a child whileenrolled in this study or within 3 months after the last dose of study drug

Study Design

Total Participants: 578
Study Start date:
September 19, 2012
Estimated Completion Date:
January 23, 2019

Study Description

This is a randomized (patients will be assigned by chance to study treatments), double-blind (patients and study personnel will not know the identity of study treatments), placebo (an inactive substance that is compared with a drug to test whether the drug has a real effect in a clinical trial)-controlled study to determine the benefits and risks of combining ibrutinib with bendamustine and rituximab (BR) in patients with relapsed or refractory CLL/SLL following at least 1 line of prior systemic therapy. Approximately 580 patients will be randomized in a 1:1 ratio to either treatment arm A (placebo) or treatment arm B (ibrutinib 420 mg).

Study medication will be administered orally once daily on a continuous schedule. All patients will receive BR as the background therapy plus either ibrutinib or placebo for a maximum of 6 cycles, after which treatment with ibrutinib or placebo will continue until disease progression or unacceptable toxicity.

A treatment cycle will be defined as 28 days. The study will include a screening phase, a treatment phase, and a follow-up phase. Study end is defined as when either 80% of the patients have died or 5 years after the last patient is randomized into the study, whichever occurs first.

Patients in treatment arm A (placebo) who complete the treatment phase, with disease progression or (after interim analysis) meet International Workshop on Chronic Lymphocytic Leukemia (IWCLL) criteria for treatment, may crossover to ibrutinib treatment (as in treatment arm B), at the investigators discretion. This open-label, next-line treatment with ibrutinib will continue until disease progression, unacceptable toxicity, withdrawal from study, or until the study end, whichever occurs earlier. One interim analysis is planned for the study. Efficacy evaluations will include computed tomography scans, laboratory testing, focused physical examinations, bone marrow biopsy and aspirate, and assessment of patient-reported outcomes. In both treatment arms, samples for the development of a population-based pharmacokinetic (PK; study of what the body does to a drug) approach will be collected. Safety will be assessed throughout the study.

Connect with a study center

  • Buenos Aires,
    Argentina

    Site Not Available

  • Ciudad Autonoma Buenos Aires,
    Argentina

    Site Not Available

  • Ciudad Autonoma de Buenos Aires,
    Argentina

    Site Not Available

  • Cordoba,
    Argentina

    Site Not Available

  • empty

    Córdoba,
    Argentina

    Site Not Available

  • empty

    La Plata,
    Argentina

    Site Not Available

  • empty

    San Miguel De Tucuman,
    Argentina

    Site Not Available

  • Aalst,
    Belgium

    Site Not Available

  • Brugge,
    Belgium

    Site Not Available

  • Brussels,
    Belgium

    Site Not Available

  • Gent,
    Belgium

    Site Not Available

  • Leuven,
    Belgium

    Site Not Available

  • empty

    Paraná,
    Brazil

    Site Not Available

  • empty

    Paraná,
    Brazil

    Site Not Available

  • empty

    Porto Alegre,
    Brazil

    Site Not Available

  • Rio de Janeiro,
    Brazil

    Site Not Available

  • Salvador,
    Brazil

    Site Not Available

  • Sao Paulo,
    Brazil

    Site Not Available

  • empty

    Calgary, Alberta
    Canada

    Site Not Available

  • Edmonton, Alberta
    Canada

    Site Not Available

  • Vancouver N/a, British Columbia
    Canada

    Site Not Available

  • Hamilton, Ontario
    Canada

    Site Not Available

  • London, Ontario
    Canada

    Site Not Available

  • Ottawa, Ontario
    Canada

    Site Not Available

  • Toronto, Ontario
    Canada

    Site Not Available

  • Montreal, Quebec
    Canada

    Site Not Available

  • Bogota,
    Colombia

    Site Not Available

  • Floridablanca,
    Colombia

    Site Not Available

  • empty

    Floridablanca-Santander,
    Colombia

    Site Not Available

  • empty

    Praha,
    Czech Republic

    Site Not Available

  • empty

    Praha 2 N/A,
    Czech Republic

    Site Not Available

  • Brno,
    Czechia

    Site Not Available

  • Praha 10,
    Czechia

    Site Not Available

  • Praha 2,
    Czechia

    Site Not Available

  • Creteil,
    France

    Site Not Available

  • Montpellier,
    France

    Site Not Available

  • Paris Cedex 13,
    France

    Site Not Available

  • Pessac,
    France

    Site Not Available

  • Pierre Benite,
    France

    Site Not Available

  • Tours,
    France

    Site Not Available

  • Villejuif,
    France

    Site Not Available

  • empty

    Amberg,
    Germany

    Site Not Available

  • Aschaffenburg,
    Germany

    Site Not Available

  • Augsburg,
    Germany

    Site Not Available

  • Dresden,
    Germany

    Site Not Available

  • Erlangen,
    Germany

    Site Not Available

  • Essen,
    Germany

    Site Not Available

  • Frankfurt,
    Germany

    Site Not Available

  • empty

    Frankfurt/Oder,
    Germany

    Site Not Available

  • Frechen,
    Germany

    Site Not Available

  • empty

    Hamburg,
    Germany

    Site Not Available

  • Hamm,
    Germany

    Site Not Available

  • Heidelberg,
    Germany

    Site Not Available

  • empty

    Homburg,
    Germany

    Site Not Available

  • Homburg/Saar,
    Germany

    Site Not Available

  • Kassel,
    Germany

    Site Not Available

  • Kiel,
    Germany

    Site Not Available

  • Koblenz,
    Germany

    Site Not Available

  • Köln,
    Germany

    Site Not Available

  • Kÿln N/a,
    Germany

    Site Not Available

  • empty

    Landshut,
    Germany

    Site Not Available

  • Lebach,
    Germany

    Site Not Available

  • Magdeburg,
    Germany

    Site Not Available

  • Mannheim,
    Germany

    Site Not Available

  • Marburg,
    Germany

    Site Not Available

  • Mutlangen,
    Germany

    Site Not Available

  • empty

    München,
    Germany

    Site Not Available

  • empty

    Tübingen,
    Germany

    Site Not Available

  • Ulm,
    Germany

    Site Not Available

  • empty

    Villingen-Schwenningen,
    Germany

    Site Not Available

  • Würzburg,
    Germany

    Site Not Available

  • empty

    Alexandroupolis,
    Greece

    Site Not Available

  • Athens,
    Greece

    Site Not Available

  • empty

    Ioannina,
    Greece

    Site Not Available

  • Thessalonikis,
    Greece

    Site Not Available

  • Haifa,
    Israel

    Site Not Available

  • Jerusalem,
    Israel

    Site Not Available

  • empty

    Naharia,
    Israel

    Site Not Available

  • Nahariya,
    Israel

    Site Not Available

  • Netanya,
    Israel

    Site Not Available

  • Petah Tikva,
    Israel

    Site Not Available

  • Ramat-Gan,
    Israel

    Site Not Available

  • Tel Aviv,
    Israel

    Site Not Available

  • Seoul,
    Korea, Republic of

    Site Not Available

  • empty

    Ciudad De Mexico,
    Mexico

    Site Not Available

  • Mexico,
    Mexico

    Site Not Available

  • empty

    Mexico D.F.,
    Mexico

    Site Not Available

  • Monterrey,
    Mexico

    Site Not Available

  • Oaxaca,
    Mexico

    Site Not Available

  • empty

    Yucatán,
    Mexico

    Site Not Available

  • empty

    Yucatán,
    Mexico

    Site Not Available

  • Brzozow,
    Poland

    Site Not Available

  • empty

    Chorzow,
    Poland

    Site Not Available

  • Chorzów,
    Poland

    Site Not Available

  • empty

    Gdynia,
    Poland

    Site Not Available

  • empty

    Katowice,
    Poland

    Site Not Available

  • Krakow,
    Poland

    Site Not Available

  • empty

    Legnica,
    Poland

    Site Not Available

  • empty

    Lublin,
    Poland

    Site Not Available

  • Opole,
    Poland

    Site Not Available

  • Slupsk,
    Poland

    Site Not Available

  • empty

    Braga,
    Portugal

    Site Not Available

  • Coimbra,
    Portugal

    Site Not Available

  • Lisboa,
    Portugal

    Site Not Available

  • Ponta Delgada,
    Portugal

    Site Not Available

  • Porto,
    Portugal

    Site Not Available

  • empty

    San Juan,
    Puerto Rico

    Site Not Available

  • Arkhangelsk,
    Russian Federation

    Site Not Available

  • Dzerzhinsk,
    Russian Federation

    Site Not Available

  • Ekaterinburg,
    Russian Federation

    Site Not Available

  • empty

    Izhevsk,
    Russian Federation

    Site Not Available

  • empty

    Kazan,
    Russian Federation

    Site Not Available

  • Krasnodar,
    Russian Federation

    Site Not Available

  • Moscow,
    Russian Federation

    Site Not Available

  • Moscow N/a,
    Russian Federation

    Site Not Available

  • Nizhniy Novgorod,
    Russian Federation

    Site Not Available

  • Obninsk,
    Russian Federation

    Site Not Available

  • empty

    Obninsk N/A,
    Russian Federation

    Site Not Available

  • Perm,
    Russian Federation

    Site Not Available

  • Rostov-Na-Donu,
    Russian Federation

    Site Not Available

  • Ryazan,
    Russian Federation

    Site Not Available

  • Saint Petersburg,
    Russian Federation

    Site Not Available

  • Samara,
    Russian Federation

    Site Not Available

  • Sochi,
    Russian Federation

    Site Not Available

  • St. Petersburg,
    Russian Federation

    Site Not Available

  • St.-Petersburg,
    Russian Federation

    Site Not Available

  • Syktyvkar,
    Russian Federation

    Site Not Available

  • Barcelona,
    Spain

    Site Not Available

  • L'hospitalet De Llobregat,
    Spain

    Site Not Available

  • Madrid,
    Spain

    Site Not Available

  • empty

    Marbella,
    Spain

    Site Not Available

  • Salamanca,
    Spain

    Site Not Available

  • Valencia,
    Spain

    Site Not Available

  • Göteborg,
    Sweden

    Site Not Available

  • Huddinge,
    Sweden

    Site Not Available

  • Stockholm,
    Sweden

    Site Not Available

  • UMEå,
    Sweden

    Site Not Available

  • Ankara,
    Turkey

    Site Not Available

  • Istanbul,
    Turkey

    Site Not Available

  • Izmir,
    Turkey

    Site Not Available

  • Kayseri,
    Turkey

    Site Not Available

  • Cherkassy,
    Ukraine

    Site Not Available

  • Dnepropetrovsk,
    Ukraine

    Site Not Available

  • Donetsk,
    Ukraine

    Site Not Available

  • empty

    Ivano-Frankivsk,
    Ukraine

    Site Not Available

  • Khakhiv,
    Ukraine

    Site Not Available

  • empty

    Kharkiv,
    Ukraine

    Site Not Available

  • Khmelnitskiy,
    Ukraine

    Site Not Available

  • Kiev,
    Ukraine

    Site Not Available

  • Lviv,
    Ukraine

    Site Not Available

  • empty

    Poltava,
    Ukraine

    Site Not Available

  • empty

    Simferopol,
    Ukraine

    Site Not Available

  • Vinnitsa,
    Ukraine

    Site Not Available

  • empty

    Zhytomyr,
    Ukraine

    Site Not Available

  • Birmingham,
    United Kingdom

    Site Not Available

  • Harrow,
    United Kingdom

    Site Not Available

  • Plymouth,
    United Kingdom

    Site Not Available

  • Sheffield Yorks,
    United Kingdom

    Site Not Available

  • Sutton,
    United Kingdom

    Site Not Available

  • Birmingham, Alabama
    United States

    Site Not Available

  • Phoenix, Arizona
    United States

    Site Not Available

  • empty

    Fayetteville, Arkansas
    United States

    Site Not Available

  • Berkeley, California
    United States

    Site Not Available

  • Duarte, California
    United States

    Site Not Available

  • Greenbrae, California
    United States

    Site Not Available

  • empty

    La Jolla, California
    United States

    Site Not Available

  • empty

    San Francisco, California
    United States

    Site Not Available

  • empty

    Denver, Colorado
    United States

    Site Not Available

  • empty

    New Haven, Connecticut
    United States

    Site Not Available

  • Stamford, Connecticut
    United States

    Site Not Available

  • Washington, District of Columbia
    United States

    Site Not Available

  • empty

    Washington, D.C., District of Columbia
    United States

    Site Not Available

  • Boca Raton, Florida
    United States

    Site Not Available

  • Jacksonville, Florida
    United States

    Site Not Available

  • Atlanta, Georgia
    United States

    Site Not Available

  • empty

    Augusta, Georgia
    United States

    Site Not Available

  • Marietta, Georgia
    United States

    Site Not Available

  • Chicago, Illinois
    United States

    Site Not Available

  • empty

    Rolling Meadows, Illinois
    United States

    Site Not Available

  • Springfield, Illinois
    United States

    Site Not Available

  • Fort Wayne, Indiana
    United States

    Site Not Available

  • Goshen, Indiana
    United States

    Site Not Available

  • Indianapolis, Indiana
    United States

    Site Not Available

  • Iowa City, Iowa
    United States

    Site Not Available

  • empty

    Topeka, Kansas
    United States

    Site Not Available

  • Westwood, Kansas
    United States

    Site Not Available

  • empty

    Lexington, Kentucky
    United States

    Site Not Available

  • Louisville, Kentucky
    United States

    Site Not Available

  • Paducah, Kentucky
    United States

    Site Not Available

  • Marrero, Louisiana
    United States

    Site Not Available

  • Baltimore, Maryland
    United States

    Site Not Available

  • empty

    Boston, Massachusetts
    United States

    Site Not Available

  • Worcester, Massachusetts
    United States

    Site Not Available

  • Ann Arbor, Michigan
    United States

    Site Not Available

  • Battle Creek, Michigan
    United States

    Site Not Available

  • Detroit, Michigan
    United States

    Site Not Available

  • Lansing, Michigan
    United States

    Site Not Available

  • empty

    Ypsilanti, Michigan
    United States

    Site Not Available

  • Saint Louis, Missouri
    United States

    Site Not Available

  • empty

    St. Louis, Missouri
    United States

    Site Not Available

  • Lincoln, Nebraska
    United States

    Site Not Available

  • Lebanon, New Hampshire
    United States

    Site Not Available

  • Hackensack, New Jersey
    United States

    Site Not Available

  • Albuquerque, New Mexico
    United States

    Site Not Available

  • empty

    Bronx, New York
    United States

    Site Not Available

  • Dunkirk, New York
    United States

    Site Not Available

  • Hawthorne, New York
    United States

    Site Not Available

  • New York, New York
    United States

    Site Not Available

  • empty

    Rochester, New York
    United States

    Site Not Available

  • empty

    Greenville, North Carolina
    United States

    Site Not Available

  • Bismarck, North Dakota
    United States

    Site Not Available

  • empty

    Fargo, North Dakota
    United States

    Site Not Available

  • Cleveland, Ohio
    United States

    Site Not Available

  • empty

    Lawton, Oklahoma
    United States

    Site Not Available

  • Portland, Oregon
    United States

    Site Not Available

  • empty

    Monroeville, Pennsylvania
    United States

    Site Not Available

  • empty

    Philadelphia, Pennsylvania
    United States

    Site Not Available

  • Charleston, South Carolina
    United States

    Site Not Available

  • empty

    Spartanburg, South Carolina
    United States

    Site Not Available

  • Sioux Falls, South Dakota
    United States

    Site Not Available

  • empty

    Watertown, South Dakota
    United States

    Site Not Available

  • Temple, Texas
    United States

    Site Not Available

  • Morgantown, West Virginia
    United States

    Site Not Available

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.